Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2070MR)

This product GTTS-WQ2070MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets Canlupfam PDCD1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001314097.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 486213
UniProt ID A0A090BAM7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ2070MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8480MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ1100MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ1593MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ5133MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ14880MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ6626MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ10836MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ14553MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR156597
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW